Article Text


PTU-124 An External Validation Of The Hepatoma Arterial-embolisation Prognosis (hap) Score: The Liverpool Experience
  1. O Noorullah1,
  2. VP Lekharaju2,
  3. IU Din3,
  4. J Klcova3,
  5. T Cross4,
  6. J Evans5,
  7. R Sturgess1,
  8. D Palmer6,
  9. E O’Grady3,
  10. N Stern1
  1. 1Digestive Diseases Unit, Liverpool, UK
  2. 2Aintree University Hospital, Liverpool, UK
  3. 3Department of Radiology, Aintree University Hospital, UK
  4. 4Department of Gastroenterology, Royal Liverpool University Hospital
  5. 5Department of Radiology, Royal Liverpool University Hospital
  6. 6University of Liverpool, Liverpool, UK


Introduction Most Hepatocellular Carcinomas (HCCs) have palliative treatment. Trans-arterial embolisation (TAE) or chemoembolisation (TACE) are used with variable results. The HAP score was recently described to determine patients likely to benefit from TAE or TACE. We report our experience with TAE and TACE to assess whether the HAP score was valid for our cohort of patients.

Methods Retrospective review of cases given TAE or TACE in Liverpool, UK (2006–2013). HAP score [1 point each for albumin < 36 g/dl, AFP > 400 ng/ml, Bilirubin > 17 µmol/l, tumour diameter > 7cm. HAP A = 0 points, B = 1, C = 2, D >2]. Outcome recorded according to HAP score.

Results 137 patients identified having received TAE/TACE with full data to complete HAP score. Mean age 69; 116 (84.7%) male. 78.8% AUH, 21.2% RLUH. HAP score A: 44 (32.1%); B: 40 (29.2%); C: 32 (23.4%); D: 21 (15.3%). Overall median survival 492 days (16 months). Median survival by HAP score, A: 492 days; B: 839 days; C 478 days; D 309 days. Log rank p < 0.001. Survival at 1 year: A 62.8%; B 75%; C59.4%, D 28.6%. Survival at 2 years: A 29.5%, B 52.5%, C 37.5%, D 14.3%. HAP D patients had lower median survival (309 vs. 563 days; p < 0.001) and 1 and 2 year survival (28.6 vs. 65.5%; p = 0.001 and 14.3 vs 39.7%; p = 0.021).

Conclusion Patients with HAP score D due TACE have a relatively poor outcome in this external validation group. This should be considered when planning treatment or further trials.

Reference Kadalayil et al. Annals of Oncology 2013

Disclosure of Interest None Declared.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.